We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
27.50 | 1.59% | 1,761.00 | 1,757.50 | 1,758.00 | 1,767.00 | 1,736.00 | 1,736.00 | 14,302,622 | 16:35:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.69 | 72.38B |
Date | Subject | Author | Discuss |
---|---|---|---|
15/6/2020 09:46 | "ianood13 Jun '20 - 16:05 - 21448 of 21454 GtG - I suggest that you read post 21440 and then apologise to Gateside!" How is that post relevant to the subsequent claim Gateside made? Because post 21442 makes it crystal clear that Monty has heard of an ISA. And Gateside's post, 21446, asking whether he has heard of an ISA comes AFTER the post clearly stating he has!!!!!! How is an apology therefore needed? Sorry, don't see the issue. Last time I looked 21446 comes AFTER 21442 and not before. | geckotheglorious | |
15/6/2020 09:30 | ViiV Healthcare on Friday said the US Food & Drug Administration has approved Tivicay PD tablets, an HIV drug, for oral suspension. Here is the 'news': ViiV is a specialist human immunodeficiency virus company, majority-owned by GlaxoSmithKline PLC, with Pfizer Inc and Shionogi Ltd as shareholders. Tivicay PD tablets are used in combination with other antiretroviral agents for the treatment of HIV type 1 infection in paediatric patients aged at least four weeks and weighing at least 3 kilograms, as well as an extended indication to expand the use of the already approved Tivicay tablet in paediatric HIV patients weighing 20 kilograms and above. The FDA approval is based on data from the ongoing P1093 and Odyssey studies. "We now need to continue our efforts to ensure this new dispersible formulation is available to children who need it around the world, in line with our mission to leave no person living with HIV behind," said ViiV Chief Executive Deborah Waterhouse. | tradermichael | |
15/6/2020 09:06 | Perhaps if RNS was offering 1 free toilet roll with every 1k shares, The affect may be positive !! | roybel | |
15/6/2020 09:04 | What RNS ? Have I missed something ? | rik shaw | |
15/6/2020 08:17 | Great rns doesn't stop gsk getting hammered! | spoole5 | |
15/6/2020 07:57 | Great rns today, FTSE looks ugly, pharmaceuticals the place to be. | montyhedge | |
13/6/2020 23:40 | Thanks... As it would help if people read more than one post, especially if they have the tendancy to be rude. | gateside | |
13/6/2020 16:05 | GtG - I suggest that you read post 21440 and then apologise to Gateside! | ianood | |
12/6/2020 16:47 | Gateside. I'm guessing you struggle to read Monty earlier today "montyhedge12 Post 21442 of 21446 I have GSK in an Isa just stating a fact" | geckotheglorious | |
12/6/2020 15:23 | Monty have you not heard of an ISA?Tax free! | gateside | |
12/6/2020 14:19 | Astra completely transformed itself, GSK could do the same.If CEO gets its right selling off the right subsidiaries, then investing in research 2500p in a few years time. | montyhedge | |
12/6/2020 11:06 | Just ignore him Jadetic or filter him (I've had him on filter for years). I'm guessing its just random price forecasts that he's plucked out of the air depending whether he's be 50p a point long or short on IG. If he's posted something actually worth reading by all means repost it and I'll acknowledge my error. | dr biotech | |
12/6/2020 10:54 | If CEO can get it going like AstraZenecca then they will be back to 2200p, like 20 years ago when they took over Smith Kline Beecham. | montyhedge | |
12/6/2020 10:06 | I have GSK in an Isa just stating a fact. | montyhedge | |
12/6/2020 09:16 | Monty, why don’t you just leave this site? If you think GSK is not worth bothering with just disappear—I won’t complain. | jadeticl3 | |
12/6/2020 08:50 | Paid tax income tax on that, no growth in 20 years, lol | montyhedge | |
12/6/2020 08:42 | Monty - a few figures to help you.Even if the share price does not change in next 20 years, if dividends are reinvested with today's yield of 5% an investment of £10000 would turn into £27000.The beauty of compound interest! | gateside | |
12/6/2020 08:31 | Will eventually be gobbled up if share underperformance continues, until then just collect the divis! | spoole5 | |
12/6/2020 07:45 | Shareprice below what it was 20 years ago, will be the same for the next 20 years, no growth, but you do get a piddling dividend, | montyhedge | |
11/6/2020 21:00 | Below 1600p it yields above 5% that's why. | gateside | |
11/6/2020 19:16 | Agree MH, world is waking up that all is not rosey. I`ve been thinking for a while that the markets are too high given the dire outlook of the macro economy. | dandu69 | |
11/6/2020 18:53 | Dow looking ugly, GSK 1565p in the morning. | montyhedge | |
11/6/2020 15:58 | Could be tempted to add a few at 1600p | gateside | |
11/6/2020 14:54 | Wrong thread. Toodle pip. | daveboy1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions